MarAprMayJun
↩ TodayMon23Mar
Tue24Mar
Wed25Mar
Thu26Mar
Fri27Mar
Sat28Mar
Sun29Mar
Mon30Mar
Tue31Mar
Wed1Apr
Thu2Apr
Fri3Apr
Sat4Apr
Sun5Apr
Mon6Apr
Tue7Apr
Wed8Apr
Fri10Apr
Sat11Apr
Mon13Apr
Tue14Apr
Wed15Apr
Thu16Apr
Fri17Apr
Sat18Apr
Sun19Apr
Mon20Apr
Tue21Apr
Wed22Apr
Thu23Apr
Fri24Apr
Sat25Apr
Sun26Apr
Mon27Apr
Tue28Apr
Wed29Apr
Thu30Apr
Fri1May
Sat2May
Sun3May
Mon4May
Tue5May
Wed6May
Thu7May
Fri8May
Sat9May
Sun10May
Mon11May
Tue12May
Wed13May
Thu14May
Fri15May
Sat16May
Sun17May
Mon18May
Tue19May
Wed20May
Thu21May
Fri22May
Sat23May
Sun24May
Mon25May
Tue26May
Wed27May
Thu28May
Fri29May
Sat30May
Sun31May
Mon1Jun
Tue2Jun
Wed3Jun
Thu4Jun
Fri5Jun
Sat6Jun
Sun7Jun
Mon8Jun
Tue9Jun
Wed10Jun
Thu11Jun
Fri12Jun
Sat13Jun
Sun14Jun
Mon15Jun
Tue16Jun
Wed17Jun
Thu18Jun
Fri19Jun
Sat20Jun
Sun21Jun
Mon22Jun
Wed24Jun
Thu25Jun
Fri26Jun
Sat27Jun
20 papers read · 20 surfaced · 2 stood out
Today's lead · Early Detection
Machine Learning Model Predicts Monoclonal Gammopathy Using Routine…
A machine learning model flags patients likely to develop precancerous blood protein changes years early, using only standard blood tests already done during routine checkups.
Movassagh M, Kaya C, Skordis C et al. · JCO Clin Cancer Inform
8/10
Impact score
Time to impact (est.)
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Novel or significantly improved treatment
Use of circulating tumour DNA to prospectively guide a switch from…
Blood tumor DNA levels can reliably guide melanoma patients to switch treatments within a week, potentially improving outcomes when resistance develops.
Novel or significantly improved treatmentHuman CART22.19 therapy in refractory pediatric B-ALL
A new CAR-T therapy targeting two protein markers simultaneously addresses why some children relapse after standard single-target treatments.
Novel or significantly improved treatmentResetting autoimmune disease with CAR cell therapies
CAR T cell therapy shows promise as an immune reset strategy for severe autoimmune diseases that don't respond to conventional treatments.
Novel or significantly improved treatmentOlverembatinib, a novel BCR-ABL tyrosine kinase inhibitor, exhibits…
A drug approved for leukemia shows potential activity in hard-to-treat pancreatic cancer patients who've exhausted other options.